Latest & greatest articles for Lamivudine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Lamivudine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Lamivudine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Lamivudine

61. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation Full Text available with Trip Pro

Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation Conversion from (...) intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation Han S H, Martin P, Edelstein M, Hu R, Kunder G, Holt C, Saab S, Durazo F, Goldstein L, Farmer D, Ghobrial R M, Busuttil R W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary

2003 NHS Economic Evaluation Database.

62. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. (Abstract)

Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lamivudine given during the last weeks of pregnancy in women with chronic hepatitis B has been reported to be safe. We report a case of chronic hepatitis B virus (HBV) infection in a newborn, despite suppression of HBV DNA to undetectable levels in the mother by prolonged lamivudine therapy. The newborn had raised alanine aminotransferase concentrations and was positive for HBV DNA at birth which persisted until 9 (...) months of age, despite neonatal vaccination, treatment with hepatitis B immune globulin, and high concentrations of anti-HBs. On HBV DNA sequencing, complete sequence homology and a similar precore mutation was found in the mother and child, indicating vertical transmission. Lamivudine therapy might not prevent perinatal transmission of HBV infection in every newborn.

2002 Lancet

63. Trizivir (Abacavir Sulfate, Lamivudine and Zidovudine) Tablets

Trizivir (Abacavir Sulfate, Lamivudine and Zidovudine) Tablets Drug Approval Package: Trizivir (Abacavir Sulfate, Lamivudine and Zidovudine) NDA #021205S003 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Trizivir (Abacavir Sulfate, Lamivudine and Zidovudine) Tablets Company: GlaxoWellcome Inc. Application No.: 021205S003 Approval Date: 6/04/2002 (PDF) (PDF) (PDF) Date created: March 042005 Note: Documents in PDF format require the . - - Links

2002 FDA - Drug Approval Package

64. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. (Abstract)

Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Large reductions in transmission of HIV-1 from mother to child have been achieved in more-developed countries due to the use of antiretrovirals. Short-course regimens, suitable for resource-poor countries, have also been shown to significantly reduce (...) peripartum HIV-1 transmission. We assessed the efficacy of short-course regimens with zidovudine and lamivudine in a predominantly breastfeeding population.We did a randomised, double-blind, placebo-controlled trial in South Africa, Uganda, and Tanzania. Between June, 1996, and January, 2000, HIV-1-infected mothers were randomised to one of four regimens: A, zidovudine plus lamivudine starting at 36 weeks' gestation, followed by oral intrapartum dosing and by 7 days' postpartum dosing of mothers

2002 Lancet Controlled trial quality: predicted high

65. Clinical trial of lamivudine in children with chronic hepatitis B. Full Text available with Trip Pro

Clinical trial of lamivudine in children with chronic hepatitis B. Lamivudine therapy is effective for chronic hepatitis B infection in adults. We evaluated the efficacy and tolerability of lamivudine as a treatment for chronic infection with hepatitis B virus (HBV) in children.Children with chronic hepatitis B were randomly assigned in a 2:1 ratio to receive either oral lamivudine (3 mg per kilogram of body weight; maximum, 100 mg) or placebo once daily for 52 weeks. The primary end point (...) was virologic response (defined by the absence of serum hepatitis B e antigen and serum HBV DNA) at week 52 of treatment.Of the 403 children screened, 191 were randomly assigned to receive lamivudine and 97 to receive placebo. The rate of virologic response at week 52 was higher among children who received lamivudine than among those who received placebo (23 percent vs. 13 percent, P=0.04). Lamivudine therapy was well tolerated and was also associated with higher rates of seroconversion from hepatitis B e

2002 NEJM Controlled trial quality: uncertain

66. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data

Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data Crowley S, Tognarini D, Desmond P, Lees M, Saal G Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The introduction of lamivudine as a treatment option for chronic hepatitis B (CHB) in a setting where either alpha-interferon (IFN-a) or no treatment were the options available for CHB patients (scenario

2002 NHS Economic Evaluation Database.

67. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. (Abstract)

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. Abacavir, a nucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the role of abacavir in a triple nucleoside combination regimen has not been evaluated against a standard protease inhibitor-containing regimen for initial antiretroviral treatment.To evaluate (...) antiretroviral equivalence and safety of an abacavir-lamivudine-zidovudine regimen compared with an indinavir-lamivudine-zidovudine regimen.A multicenter, phase 3, randomized, double-blind trial with an enrollment period from August 1997 to June 1998, with follow-up through 48 weeks at 73 clinical research units in the United States, Canada, Australia, and Europe.Five hundred sixty-two antiretroviral-naive, HIV-infected adults with a plasma HIV RNA level of at least 10 000 copies/mL and a CD4 cell count

2001 JAMA Controlled trial quality: predicted high

68. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States

Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States Brooks E A, Lacey L F, Payne S L, Miller D W Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Lamivudine was compared with interferon-alpha in the treatment of chronic hepatitis B in the USA. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients suffering from

2001 NHS Economic Evaluation Database.

69. Combivir (Lamivudine/Zidovudine) Tablets

Combivir (Lamivudine/Zidovudine) Tablets Drug Approval Package: Combivir (Lamivudine/Zidovudine) NDA #020857s008 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Combivir (Lamivudine/Zidovudine) Tablets Company: Glaxo Wellcome Inc. Application No.: 020857s008 Approval Date: 9/29/2000 (PDF) (PDF) (PDF) (PDF) Date created: January 102005 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information

2000 FDA - Drug Approval Package

70. Trizivir (abacavir sulfate, lamivudine, zidovudine)

Trizivir (abacavir sulfate, lamivudine, zidovudine) Drug Approval Package: Trizivir (abacavir sulfate, lamivudine, zidovudine) NDA #021205 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Trizivir (abacavir sulfate, lamivudine, zidovudine) Company: Glaxo Wellcome Application No.: 021205 Approval Date: 11/14/2000 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Administrative Document(s) & Correspondence (PDF) (PDF) Date created: March 282004 Note

2000 FDA - Drug Approval Package

71. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy Full Text available with Trip Pro

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy An efficacy and cost-effectiveness analysis (...) of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy Han S H, Ofman J, Holt C, King K, Kunder G, Chen P, Dawson S, Goldstein L, Yersiz H, Farmer D G, Ghobrial R M, Busuttil R W, Martin P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results

2000 NHS Economic Evaluation Database.

72. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B

Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B Crowley S J, Tognarini D, Desmond P V, Lees M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Drug therapies for the treatment of the hepatitis B virus (HBV). Specifically these included interferon-alpha and lamivudine, a nucleoside analogue. Type of intervention Treatment. Economic study type Cost-effectiveness analysis; cost-utility analysis. Study population A hypothetical, typical population cohort of patients in Australia with chronic HBV. All patients were positive

2000 NHS Economic Evaluation Database.

73. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. (Abstract)

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. Efavirenz is a nonnucleoside reverse-transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). We compared two regimens containing efavirenz, one with a protease inhibitor and the other with two nucleoside reverse-transcriptase inhibitors, with a standard three-drug regimen.The study subjects were 450 (...) patients who had not previously been treated with lamivudine or any nonnucleoside reverse-transcriptase inhibitor or protease inhibitor. In this open-label study, patients were randomly assigned to one of three regimens: efavirenz (600 mg daily) plus zidovudine (300 mg twice daily) and lamivudine (150 mg twice daily); the protease inhibitor indinavir (800 mg every eight hours) plus zidovudine and lamivudine; or efavirenz plus indinavir (1000 mg every eight hours).Suppression of plasma HIV-1 RNA

1999 NEJM Controlled trial quality: uncertain

74. Lamivudine as initial treatment for chronic hepatitis B in the United States. (Abstract)

Lamivudine as initial treatment for chronic hepatitis B in the United States. Although the nucleoside analogue lamivudine has shown promise in patients with chronic hepatitis B, long-term data on patients from the United States are lacking. We randomly assigned previously untreated patients with chronic hepatitis B to receive either 100 mg of oral lamivudine or placebo daily for 52 weeks. We then followed them for an additional 16 weeks to evaluate post-treatment safety and the durability (...) of responses. The primary end point with respect to efficacy was a reduction of at least 2 points in the score on the Histologic Activity Index. On this scale, scores can range from 0 (normal) to 22 (most severe abnormalities).Of the 143 randomized patients, 137 were included in the efficacy analysis: 66 in the lamivudine group and 71 in the placebo group. The other six patients were excluded at the base-line visit because of the absence of a documented history of hepatitis B surface antigen for at least

1999 NEJM Controlled trial quality: uncertain

75. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regiments for HIV infection in the US

A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regiments for HIV infection in the US A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regiments for HIV infection in the US A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regiments for HIV infection in the US Lacey L, Mauskopf J, Lindrooth R, Pham S, Saag M (...) , Sawyer W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The addition of lamivudine to zidovudine-containing antiretroviral regimens for treating patients with human immunodeficiency virus (HIV) was investigated. No further details

1999 NHS Economic Evaluation Database.

76. Quantitative assessment of hepatitis B virus DNA during a 24-week course of lamivudine therapy. (Abstract)

Quantitative assessment of hepatitis B virus DNA during a 24-week course of lamivudine therapy. 9537953 1998 04 09 2013 11 21 0003-4819 128 8 1998 Apr 15 Annals of internal medicine Ann. Intern. Med. Quantitative assessment of hepatitis B virus DNA during a 24-week course of lamivudine therapy. 697 Honkoop P P de Man R A RA Niesters H G HG eng Clinical Trial Letter Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 0 Antiviral Agents 0 DNA, Viral 2T8Q726O95 Lamivudine (...) AIM IM X Antiviral Agents administration & dosage DNA, Viral blood Drug Administration Schedule Hepatitis B drug therapy virology Humans Lamivudine administration & dosage Polymerase Chain Reaction 1998 12 16 1998 12 16 0 1 1998 12 16 0 0 ppublish 9537953

1998 Annals of Internal Medicine Controlled trial quality: uncertain

77. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. (Abstract)

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. Combination antiretroviral therapy can markedly suppress human immunodeficiency virus (HIV) replication but the duration of HIV suppression varies among patients.To compare the antiretroviral effect of a 3-drug regimen started simultaneously or sequentially in patients with HIV infection.A multicenter, randomized, double-blind study, modified after at least 24 (...) weeks of blinded therapy to provide open-label 3-drug therapy with follow-up through 100 weeks.Four clinical research unitsNinety-seven patients with HIV infection who had taken zidovudine for at least 6 months with serum HIV RNA level of at least 20000 copies/mL and CD4 cell count of 0.05 to 0.40 x 10(9)/L.Patients were initially randomized to receive 1 of 3 antiretroviral regimens: indinavir, 800 mg every 8 hours; zidovudine, 200 mg every 8 hours and lamivudine, 150 mg every 12 hours; or all 3

1998 JAMA Controlled trial quality: uncertain

78. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Full Text available with Trip Pro

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. In preliminary trials, lamivudine, an oral nucleoside analogue, has shown promise for the treatment of chronic hepatitis B. We conducted a one-year, double-blind trial of lamivudine in 358 Chinese patients with chronic hepatitis B. The patients were randomly assigned to receive 25 mg of lamivudine (142 patients), 100 mg of lamivudine (143), or placebo (73) orally once daily. The patients underwent (...) liver biopsies before entering the study and after completing the assigned treatment regimen. The primary end point was a reduction of at least two points in the Knodell necroinflammatory score.Hepatic necroinflammatory activity improved by two points or more in 56 percent of the patients receiving 100 mg of lamivudine, 49 percent of those receiving 25 mg of lamivudine, and 25 percent of those receiving placebo (P<0.001 and P=0.001, respectively, for the comparisons of lamivudine treatment

1998 NEJM Controlled trial quality: predicted high

79. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team (Abstract)

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team The long-term effectiveness of potent three-drug antiretroviral regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection is limited by problems related to compliance and tolerability. We investigated whether two-drug (...) maintenance therapy would suppress viral replication after a three-month period of aggressive triple-drug induction therapy.A total of 378 HIV-1-infected adults who had not received previous antiretroviral treatment received three months of induction therapy consisting of 300 mg of zidovudine every 12 hours, 150 mg of lamivudine every 12 hours, and 800 mg of indinavir every 8 hours. The 279 patients in whom the plasma HIV-1 RNA titer fell below 500 copies per milliliter after two months of triple-drug

1998 NEJM Controlled trial quality: uncertain

80. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. (Abstract)

Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Treatment and prevention of HIV-1-related central-nervous-system disease may be dependent on penetration of antiretroviral drugs into the central nervous system. Few data are available about cerebrospinal-fluid penetration and concomitant changes of HIV-1-RNA concentrations during treatment with antiretroviral agents. We investigated these effects in HIV-1-infected people.28 (...) antiretroviral-naive individuals with CD4 cell counts of 200/microL or more and plasma HIV-1-RNA concentrations of 10,000 or more copies/mL who were free of neurological symptoms were randomly assigned lamivudine plus either stavudine (n = 17) or zidovudine (n = 11). We did lumbar punctures on 28 individuals before and 22 individuals after 12 weeks of treatment to assess HIV-1-RNA and drug concentrations in cerebrospinal fluid.All 28 individuals had detectable HIV-1-RNA concentrations in the cerebrospinal

1998 Lancet Controlled trial quality: uncertain